HES6 drives a critical AR transcriptional programme to induce castration‐resistant prostate cancer through activation of an E2F1‐mediated cell cycle network by Ramos-Montoya, A, Lamb, A, Russell, R, Carroll, T, Jurmeister, S, Galeano-Dalmau, N, Massie, C, Boren, J, Bon, H, Theodorou, V, Vias, M, Shaw, G, Sharma, N, Ross-Adams, H, Scott, H, Vowler, S, Howat, W, Warren, A, Wooster, R, Mills, I, Neal, D

Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics by Li, X, Francies, H, Secrier, M, Perner, J, Miremadi, A, Galeano-Dalmau, N, Barendt, W, Letchford, L, Leyden, G, Goffin, E, Barthorpe, A, Lightfoot, H, Chen, E, Gilbert, J, Noorani, A, Devonshire, G, Bower, L, Grantham, A, Macrae, S, Grehan, N, Wedge, D, Fitzgerald, R, Garnett, M

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance by Secrier, M, Li, X, De Silva, N, Eldridge, MD, Contino, G, Bornschein, J, Macrae, S, Grehan, N, O'Donovan, M, Miremadi, A, Yang, T-P, Bower, L, Chettouh, H, Crawte, J, Galeano-Dalmau, N, Grabowska, A, Saunders, J, Underwood, T, Waddell, N, Barbour, AP, Nutzinger, B, Achilleos, A, Edwards, PAW, Lynch, AG, Tavaré, S, Fitzgerald, RC, Oesophageal Cancer Clinical And Molecular Stratification (Occams) Consortium